The Evolving Role of Nonstatin Medication in the Management of Hypercholesterolemia

After watching the webcast you will be automatically forwarded to the evaluation to earn your CME credits.

Speaker Name/Credentials

Joseph Saseen, PharmD, CLS

Time of Talk

45 minutes

CME Accreditation

45 min webcast = 0.75 credits
15 min exam = 0.25 credits
Total = 1.0 credits

Description

This webcast will review several new nonstatin therapies that have been proven to reduce cardiovascular events, when added to statin therapy.

Learning Objectives

  1. Describe guideline and other expert recommendations of for the use of nonstatin therapy in the management of dyslipidemia
  2. Examine results from cardiovascular outcome trials evaluating non-statin therapies
  3. Review the mechanism of action, efficacy and safety of new and novel LDL-cholesterol lowering medications

Disclosures

none

This enduring material activity, The Evolving Role of Nonstatin Medication in the Management of Hypercholesterolemia, has been reviewed and is acceptable for up to 1.0 prescribed credits by the American Academy of Family Physicians. Term of approval begins October 12, 2020. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Fighting the Ladykiller (and side effects) with Cholesterol Lowering Therapy

After watching the webcast you will be automatically forwarded to the evaluation to earn your CME credits.

Speaker Name/Credentials

Margo B. Minissian, PhD, ACNP

Time of Talk

45 minutes

CME Accreditation

45 min webcast = 0.75 credits
15 min exam = 0.25 credits
Total = 1.0 credits

Description

This webcast will focus on lowering cardiovascular risk in women through effective cholesterol management and addressing issues like statin myalgias.

Learning Objectives

  1. Provide two examples why management of cholesterol is different in women compared to men.
  2. List 4 classifications of patients who qualify for statin therapy
  3. Describe 2 clinical pearls to improve statin associated muscle symptoms

Disclosures

none

This enduring material activity, Fighting the Ladykiller (and side effects) with Cholesterol Lowering Therapy, has been reviewed and is acceptable for up to 1.0 prescribed credits by the American Academy of Family Physicians. Term of approval begins October 12, 2020. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Should We Measure Lipoprotein(a) and What Should We Do With the Results?

After watching the webcast you will be automatically forwarded to the evaluation to earn your CME credits.

Speaker Name/Credentials

Samia Mora, MD, MHS

Time of Talk

45 minutes

CME Accreditation

45 min webcast = 0.75 credits
15 min exam = 0.25 credits
Total = 1.0 credits

Description

This webcast will review how Lp(a), a genetically derived LDL-like-particle, can increase cardiovascular risk

Learning Objectives

  1. To discuss prevalence, screening, and measurement of lipoprotein(a)
  2. To summarize the relationship of lipoprotein(a) with cardiometabolic risk
  3. To discuss treatment strategies for high lipoprotein(a)

Disclosures

Institutional research grant to the Brigham and Women’s Hospital from Atherotech Diagnostics (2018)

Quest Diagnostics measured Lp(a) in the JUPITER trial

This enduring material activity, Should We Measure Lipoprotein(a) and What Should We Do With the Results?, has been reviewed and is acceptable for up to 1.0  prescribed credits by the American Academy of Family Physicians. Term of approval begins July 1, 2020. Term of approval is for one year from this date. Physicians should claim only the credit commensurate with the extent of their participation in the activity.